John R de Almeida1, Alan J Moskowitz2, Brett A Miles3, David P Goldstein1, Marita S Teng3, Andrew G Sikora3, Vishal Gupta4, Marshall Posner5, Eric M Genden3. 1. Department of Otolaryngology-Head and Neck Surgery, Princess Margaret Hospital, Toronto, Canada. 2. Departments of Health Evidence & Policy and Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. 3. Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York. 4. Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York. 5. Department of Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.
Abstract
BACKGROUND: The present study is an economic evaluation comparing transoral robotic surgery (TORS) to (chemo)radiotherapy for the management of early T-classification oropharyngeal cancer. METHODS: A societal perspective was adopted. Treatment for TORS and (chemo)radiotherapy were modeled using decision analysis and recurrences were modeled over a 10 year horizon with a Markov model. Model parameters were derived from systematic review. Deterministic and probabilistic sensitivity analyses were used to test model robustness. RESULTS: TORS demonstrated a cost savings of $1366 and an increase of 0.25 quality-adjusted life years (QALYs) per case in comparison to (chemo)radiotherapy. TORS was sensitive to variations in adjuvant therapy, costs, utilities, complications, and recurrence rates in deterministic and probabilistic sensitivity analysis. In two-way sensitivity analysis, with increasing adjuvant therapy for TORS and decreasing concurrent chemotherapy for radiotherapy, TORS is decreasingly cost-effective. CONCLUSION: TORS is cost-effective for treatment of early oropharyngeal cancer. Case selection to minimize adjuvant therapy ensures cost-effective treatment.
BACKGROUND: The present study is an economic evaluation comparing transoral robotic surgery (TORS) to (chemo)radiotherapy for the management of early T-classification oropharyngeal cancer. METHODS: A societal perspective was adopted. Treatment for TORS and (chemo)radiotherapy were modeled using decision analysis and recurrences were modeled over a 10 year horizon with a Markov model. Model parameters were derived from systematic review. Deterministic and probabilistic sensitivity analyses were used to test model robustness. RESULTS:TORS demonstrated a cost savings of $1366 and an increase of 0.25 quality-adjusted life years (QALYs) per case in comparison to (chemo)radiotherapy. TORS was sensitive to variations in adjuvant therapy, costs, utilities, complications, and recurrence rates in deterministic and probabilistic sensitivity analysis. In two-way sensitivity analysis, with increasing adjuvant therapy for TORS and decreasing concurrent chemotherapy for radiotherapy, TORS is decreasingly cost-effective. CONCLUSION:TORS is cost-effective for treatment of early oropharyngeal cancer. Case selection to minimize adjuvant therapy ensures cost-effective treatment.
Authors: Jennifer R Cracchiolo; Benjamin R Roman; David I Kutler; William I Kuhel; Marc A Cohen Journal: J Surg Oncol Date: 2016-07-08 Impact factor: 3.454
Authors: Kathryn R Tringale; Kate T Carroll; Kaveh Zakeri; Assuntina G Sacco; Linda Barnachea; James D Murphy Journal: J Natl Cancer Inst Date: 2018-05-01 Impact factor: 13.506
Authors: Joseph R Acevedo; Katherine E Fero; Bayard Wilson; Assuntina G Sacco; Loren K Mell; Charles S Coffey; James D Murphy Journal: J Clin Oncol Date: 2016-11-10 Impact factor: 44.544
Authors: David J Sher; Abiy Agiro; Siting Zhou; Andrew T Day; Andrea DeVries Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-10-01 Impact factor: 6.223
Authors: Kevin Motz; Hsien-Yen Chang; Harry Quon; Jeremy Richmon; David W Eisele; Christine G Gourin Journal: JAMA Otolaryngol Head Neck Surg Date: 2017-06-01 Impact factor: 6.223
Authors: S N Rogers; R S Pinto; J Lancaster; F Bekiroglu; D Lowe; S Tandon; T M Jones Journal: Eur Arch Otorhinolaryngol Date: 2016-04-18 Impact factor: 2.503